Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity ...Middle East

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also published in Arthritis & Rheumatology INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli...

Hence then, the article about phase 3b data presented at aad annual meeting show lilly s taltz ixekizumab plus zepbound tirzepatide delivered superior efficacy for adults with psoriatic arthritis and obesity was published today ( Saturday 28/03/2026 - 10:17 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity )

Also on site :

• Peter Alexander is leaving NBC after years of being passed over for top anchor jobs: source
• London anti far-right march – latest: Police brace for unrest as thousands of protesters descend on capital
• Ignore the bombast – the Iran war is only likely to end one way